Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Metabolic Partnering Deal Trends, Players and Financials 2012-2018 -

Research and Markets
Posted on: 07 Mar 18

The "Global Metabolic Partnering 2012-2018: Deal trends, players and financials" report has been added to's offering.

Global Metabolic Partnering 2012 to 2018 provides the full collection of Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Metabolic partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Metabolic technologies and products.

Report scope

Global Metabolic Partnering 2012 to 2018 includes:

  • Trends in Metabolic dealmaking in the biopharma industry since 2012
  • Analysis of Metabolic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Metabolic deal contract documents
  • Comprehensive access to over 3500 Metabolic deal records
  • The leading Metabolic deals by value since 2012
  • Most active Metabolic dealmakers since 2012

In Global Metabolic Partnering 2012 to 2018, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

Chapter 3 - Financial deal terms for Metabolic partnering

Chapter 4 - Leading Metabolic deals and dealmakers

Chapter 5 - Metabolic contract document directory

Chapter 6 - Metabolic dealmaking by therapeutic target

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.